Allan Camaisa Joins Res Nova Biologics Advisory Board to Advance Breast Cancer Immunotherapy
Key Insights
Former Calidi Biotherapeutics (search) Chairman and CEO Allan Camaisa has joined Res Nova Biologics (search)' Advisory Board to accelerate development of breast cancer (search) immunotherapies.
Res Nova is advancing FloraStilbene™, a proprietary combination of RU-486 and pterostilbene that showed tumor regression in early trials with no adverse events in four patients.
The company is also developing ValloVax Technology, a tumor-targeted delivery system using FDA-cleared blood vessel targeting to administer cancer (search)-killing viruses intravenously.
Res Nova Biologics (search), a clinical-stage cancer (search) immunotherapy company, announced the appointment of Allan Camaisa to its Advisory Board, bringing decades of biotechnology leadership experience to advance the company's breast cancer (search) treatment programs. Camaisa, former Chairman and CEO and cofounder of Calidi Biotherapeutics (search), spent a decade developing innovative stem cells delivering oncolytic virus to attack tumors and currently serves as Board Director and Advisor to Calidi Bio.
Leadership Expertise in Biotechnology Development
"Allan Camaisa's visionary leadership and proven success in biotechnology make him an invaluable addition to our Advisory Board," said Famela Ramos, President and Chief Executive Officer of Res Nova Biologics (search). "His expertise will be instrumental in advancing Res Nova's mission to deliver transformative therapies. Additionally, his commitment to curing cancer (search), inspired by the personal loss of his father, aligns with our dedication of finding lifesaving treatments using our novel immunotherapeutic candidates."
Camaisa's career demonstrates expertise in merging technology with medical needs. At Parallel6 (search), he pioneered a digital platform that revolutionized clinical trial participant engagement, reducing enrollment bottlenecks for pharmaceutical companies including Sanofi and Pfizer. His experience in digital health and clinical trial infrastructure optimization could prove particularly valuable for Res Nova as it navigates advancing FloraStilbene™ through trials.
Dual-Pronged Immunotherapy Approach
Res Nova Biologics (search) is developing two primary breast cancer (search) immunotherapy programs. FloraStilbene™ represents a proprietary combination of RU-486 and pterostilbene, designed to stimulate immune responses in advanced breast cancer patients. Early trials demonstrated no adverse events in four patients, with tumor regression observed within three months. The drug's mechanism leverages immunological parallels between pregnancy and cancer (search), offering a novel approach in the immunotherapy landscape.
The company's second program, ValloVax Technology, utilizes a tumor-targeted delivery system that employs FDA-cleared blood vessel targeting to administer cancer (search)-killing viruses intravenously, designed to bypass systemic toxicity concerns associated with traditional approaches.
Strategic Development Pathway
Res Nova is pursuing the 505b2 regulatory pathway for FloraStilbene™, which leverages existing approvals for RU-486 to potentially reduce time-to-market risks. The company has established partnerships with Cure Stat Rx (search) for 505b2 pathway manufacturing and maintains an alliance with Dr. George Delgado, a leader in reproductive immunology and founder of Abortion Pill Reversal.
"My goal in life is to accelerate the development of cancer (search) treatments and eventual cures," said Camaisa. "The dedication, perseverance and success that Famela and her team have is second to none. I am proud to assist this extraordinary group of people in accelerating their goal of making FloraStilbene available to breast cancer (search) patients everywhere."
Distinguished Advisory Board
Res Nova's Scientific Advisory Board includes Dr. Santosh Kesari, a world-renowned neuro-oncologist ranked in the top 1% of his field by Castle Connolly Medical Ltd, Bishop Joseph Coffey from the Archdiocese for the Military Services, USA, and Dr. Michael P. Koumjian, a cardiac surgery specialist with over 46 years of experience.
Dr. George Delgado describes the company as "a beacon of diversity and excellence, uniting luminaries from varied fields. This diverse coalition of medical, scientific, and spiritual leaders ensures Res Nova's approach is both groundbreaking and grounded in a higher calling."
Clinical Development Timeline
The company is currently conducting a 10-patient proof-of-concept trial, with key clinical milestones anticipated by Q3 2025. Camaisa's experience in securing strategic partnerships, including Anakam (search)'s collaboration with the U.S. Veterans Administration, could accelerate Res Nova's clinical development processes and enhance patient recruitment capabilities.
"Res Nova Biologics (search) is not just developing treatments; we are answering a call to transform a drug known to destroy life into a cure that supports life," said Ramos. "With Allan Camaisa's strategic vision and the wisdom of our esteemed board, including Dr. Kesari's oncology second-to-none experience in cancer (search) immunotherapy, Dr. Delgado's reproductive medicine ingenuity and Bishop Coffey's moral guidance, we are poised to revolutionize breast cancer (search) therapy."